Io Biotech, Inc. rose 4.65% in premarket trading, with Innovent Biologics, Inc. announcing its 2025 interim results and major business updates. The company reported robust revenue growth and substantial profit improvement, driven by exceptional execution under a clear roadmap of dual-driven growth and global innovation.
Comments
No comments yet